Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
14 participants
OBSERVATIONAL
2019-06-12
2019-10-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
NCT00341679
Phenomics in Autoimmune and Inflammatory Diseases
NCT02466217
Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies
NCT04917705
Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
NCT05681676
Investigation of Immune Disorders and Deficiencies
NCT01981785
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Systemic Lupus Erythematosus
No interventions assigned to this group
Sjogren's Syndrome
No interventions assigned to this group
Multiple Sclerosis
No interventions assigned to this group
Systemic Sclerosis
No interventions assigned to this group
Crohn's Disease
No interventions assigned to this group
Ulcerative Colitis
No interventions assigned to this group
Inflammatory Myositis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participant or legal surrogate able and willing to provide written, informed consent.
3. Participant is, or has been undergoing care for one of the specified diseases in a participating centre with a confirmed clinical diagnosis of the specified disease.
4. Participant has or will provide the relevant peripheral blood (required) and normal practice tissue specimens (if available).
5. Participant has one of the following target auto-immune or inflammatory diseases diagnosed according to local clinical practice guidelines:
1. Crohn's Disease
2. Inflammatory myositis
3. Multiple sclerosis
4. Sjogren's syndrome
5. Systemic lupus erythematosus
6. Systemic sclerosis
7. Ulcerative colitis
Exclusion Criteria
2. Participants suffering from any additional disease that may interfere with the biomarker signals as per the investigator's discretion.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alpine Immune Sciences, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jan Hillson, MD
Role: STUDY_DIRECTOR
Alpine Immune Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GI Research Institute
Vancouver, British Columbia, Canada
Mary Pack Arthritis Center
Vancouver, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALPN000-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.